Dr. Curtis A. Baum, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 701
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
KS license 04-20536
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stormont Vail Hospital Topeka, KS
- University of Kansas Health System - St Francis Campus Topeka, KS
Medical groups
- Cotton-O'neil Clinic Revocable Trust (666 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 701
- Services billed
- 980
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 206 | 206 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 147 | 144 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 116 | 116 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 115 | 114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 72 | 47 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 61 | 42 |
| Biopsy of large bowel using a flexible endoscope | 58 | 58 |
| Diagnostic exam of large bowel using a flexible endoscope | 57 | 57 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 54 | 54 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 41 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Odt (ondansetron) Other prescribers in Topeka, KS | 279 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Topeka, KS | 255 |
| Pantoprazole Sodium Other prescribers in Topeka, KS | 230 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Topeka, KS | 178 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Topeka, KS | 101 |
| Omeprazole Other prescribers in Topeka, KS | 81 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 34 |
| Sucralfate Other prescribers in Topeka, KS | 28 |
| Esomeprazole Magnesium Other prescribers in Topeka, KS | 26 |
| Ondansetron Hcl Other prescribers in Topeka, KS | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $245 in total to this clinician.
| AbbVie Inc. | $94.50 |
|---|---|
| Janssen Biotech, Inc. | $80.01 |
| Janssen Scientific Affairs, LLC | $70.62 |
| Food and Beverage | $245 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 23 industry-funded studies in 2025, from 6 companies. The companies reported $460,902 in research payments for these studies, mostly to the institutions running them.
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)
Janssen Research & Development, LLC - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie Inc. · Active, not recruiting · NCT06880744 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie Inc. · Active, not recruiting · NCT03105102 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - Entyvio (vedolizumab) long-term safety study: an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or crohn's disease
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP)
AbbVie Inc. - An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05369832 - ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and S…
Janssen Research & Development, LLC - A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy…
Janssen Research & Development, LLC - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.